Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

INTI FERNANDEZ

Allopathic & Osteopathic Physicians General Practice

NPI
1659461101
CMS profile
75387
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$104.22

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $104.22 5

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $23.45 1
AstraZeneca Pharmaceuticals LP $22.50 1
Amgen Inc. $20.67 1
Novo Nordisk Inc $20.46 1
PFIZER INC. $17.14 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

INTI FERNANDEZ

NPI 1659461101 · CMS profile ID 75387

Allopathic & Osteopathic Physicians / General Practice

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659461101?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
INTI FERNANDEZ, NPI 1659461101, CMS profile ID 75387. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659461101?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). INTI FERNANDEZ, NPI 1659461101, CMS profile ID 75387. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659461101?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
INTI FERNANDEZ, NPI 1659461101, CMS profile ID 75387, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1659461101?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $104.22 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $20.6709/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228351952 CMS
PFIZER INC. $17.1406/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229315223 CMS
Merck Sharp & Dohme LLC $23.4504/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238150586 CMS
Novo Nordisk Inc $20.4603/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189129401 CMS
AstraZeneca Pharmaceuticals LP $22.5003/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206676647 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $59.06 4
PY2020 $15.80 1
PY2021 $68.75 4
PY2022 $37.69 2
PY2023 $109.38 6
PY2024 $406.19 11
PY2025 $104.22 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $247,458.00 56
PY2024 Principal investigator $394,912.46 60
PY2023 Principal investigator $216,893.52 51
PY2022 Principal investigator $150,151.52 34
PY2021 Principal investigator $179,866.77 30
PY2020 Principal investigator $179,109.45 79
PY2019 Principal investigator $44,348.58 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

60 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $927.00 12/31/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
M21-572 Ph3 Ped FC Trial 2-5 (LIN-MD-68) (3051-303-001) No dispute reported 06/30/2026 1100764337
Principal investigator 1 ABBVIE INC. $392.50 12/31/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
M21-862 Ph2 6 mo-2 yr old Functional Constipation Study (3051-201-001) No dispute reported 06/30/2026 1100766381
Principal investigator 1 ABBVIE INC. $1,080.00 12/31/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
LIN-MD-64 Ph3 Ped FC and IBS-C Trial 6-17 (M21-567) No dispute reported 06/30/2026 1100766383
Principal investigator 1 ABBVIE INC. $804.00 12/31/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
3030-202-002 Ph2 Dose Ranging Peds (M21-485) No dispute reported 06/30/2026 1100766385
Principal investigator 1 ABBVIE INC. $960.00 12/31/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
3030-302-002 Ph3 Pediatric Long Term Safety Study (M21-484) No dispute reported 06/30/2026 1100766387
Principal investigator 1 ABBVIE INC. $8,703.75 12/30/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100763706
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $13,591.93 12/20/2024 Non-covered Recipient Entity
Valencia Medical and Research Center
C3300-201 No dispute reported 06/30/2026 1150189360
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $16,273.24 12/20/2024 Non-covered Recipient Entity
Valencia Medical and Research Center
C3300-201 No dispute reported 06/30/2026 1150189596
Principal investigator 1 ABBVIE INC. $893.00 12/19/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100761904
Principal investigator 1 ABBVIE INC. $8,577.00 12/05/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide No dispute reported 06/30/2026 1100759907
Principal investigator 1 ABBVIE INC. $2,078.00 12/05/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) No dispute reported 06/30/2026 1100759923
Principal investigator 1 ABBVIE INC. $9,748.00 12/04/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C No dispute reported 06/30/2026 1100758455
Principal investigator 1 ABBVIE INC. $5,538.00 12/04/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children No dispute reported 06/30/2026 1100758467
Principal investigator 1 ABBVIE INC. $8,280.00 12/04/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100758713
Principal investigator 1 ABBVIE INC. $1,580.00 11/21/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C No dispute reported 06/30/2026 1100756081
Principal investigator 1 Ardelyx, Inc. $5,734.00 11/18/2024 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1146668137
Principal investigator 1 ABBVIE INC. $2,078.00 11/07/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) No dispute reported 06/30/2026 1100753767
Principal investigator 1 ABBVIE INC. $2,291.25 11/06/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation (FC) With a 24-week Open-label Treatment Extension No dispute reported 06/30/2026 1100752329
Principal investigator 1 Ardelyx, Inc. $7,262.00 10/28/2024 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1146668090
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $32,967.95 10/23/2024 Non-covered Recipient Entity
Valencia Medical and Research Center
C3300-201 No dispute reported 06/30/2026 1150190000
Principal investigator 1 ABBVIE INC. $13,901.00 10/03/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100745872
Principal investigator 1 Ardelyx, Inc. $5,467.50 09/16/2024 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1146667968
Principal investigator 1 ABBVIE INC. $2,078.00 09/04/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) No dispute reported 06/30/2026 1100740450
Principal investigator 1 ABBVIE INC. $5,194.00 09/03/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100739174
Principal investigator 1 Ardelyx, Inc. $913.50 08/26/2024 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1146667907
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $3,734.64 08/23/2024 Non-covered Recipient Entity
Valencia Medical and Research Center
C3300-201 No dispute reported 06/30/2026 1150189996
Principal investigator 1 ABBVIE INC. $3,231.00 08/02/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100733906
Principal investigator 1 ABBVIE INC. $2,078.00 07/05/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) No dispute reported 06/30/2026 1100727034
Principal investigator 1 ABBVIE INC. $8,001.00 07/05/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100727036
Principal investigator 1 ABBVIE INC. $2,825.00 07/03/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C No dispute reported 06/30/2026 1100725466
Principal investigator 1 ABBVIE INC. $1,517.00 07/03/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Linaclotide Safety and Efficacy in Pediatric Participants 6 to 17 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 1100725468
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $11,028.22 07/01/2024 Non-covered Recipient Entity
Valencia Medical and Research Center
C3300-201 No dispute reported 06/30/2026 1150189998
Principal investigator 1 Ardelyx, Inc. $4,937.00 06/11/2024 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1146667761
Principal investigator 1 ABBVIE INC. $7,806.00 06/05/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100720780
Principal investigator 1 ABBVIE INC. $914.00 06/05/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER
Linaclotide Safety and Efficacy in Pediatric Participants 6 to 17 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 1100720826
Principal investigator 1 ABBVIE INC. $18,880.00 06/05/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C No dispute reported 06/30/2026 1100720828
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,779.30 06/05/2024 Non-covered Recipient Entity
Valencia Medical and Research Center
C3300-201 No dispute reported 06/30/2026 1150189358
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $14,031.83 06/05/2024 Non-covered Recipient Entity
Valencia Medical and Research Center
C3300-201 No dispute reported 06/30/2026 1150189468
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $2,489.40 05/29/2024 Non-covered Recipient Entity
Valencia Medical and Research Center
C3300-201 No dispute reported 06/30/2026 1150189352
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $850.00 05/29/2024 Non-covered Recipient Entity
Valencia Medical and Research Center
C3300-201 No dispute reported 06/30/2026 1150189354
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $300.00 05/29/2024 Non-covered Recipient Entity
Valencia Medical and Research Center
C3300-201 No dispute reported 06/30/2026 1150189356
Principal investigator 1 ABBVIE INC. $8,774.00 05/09/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER
A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) No dispute reported 06/30/2026 1100717260
Principal investigator 1 ABBVIE INC. $2,262.00 05/08/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100716036
Principal investigator 1 ABBVIE INC. $1,806.00 05/08/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER
Linaclotide Safety and Efficacy in Pediatric Participants 6 to 17 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 1100716038
Principal investigator 1 Ardelyx, Inc. $3,000.00 04/22/2024 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1146667671
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $2,431.62 04/19/2024 Non-covered Recipient Entity
Valencia Medical and Research Center
C3300-201 No dispute reported 06/30/2026 1150189466
Principal investigator 1 ABBVIE INC. $3,028.00 04/04/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER
Linaclotide Safety and Efficacy in Pediatric Participants 6 to 17 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 1100711158
Principal investigator 1 ABBVIE INC. $4,350.00 04/04/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100711218
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $15,951.74 04/01/2024 Non-covered Recipient Entity
Valencia Medical and Research Center
C3300-201 No dispute reported 06/30/2026 1150189464
Principal investigator 1 ABBVIE INC. $3,147.32 03/27/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 1100709960
Principal investigator 1 ABBVIE INC. $13,058.00 03/07/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 1100706644
Principal investigator 1 ABBVIE INC. $1,007.00 03/07/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 1100707668
Principal investigator 1 ABBVIE INC. $1,050.00 02/01/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 1100701764
Principal investigator 1 ABBVIE INC. $17,460.00 02/01/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C No dispute reported 06/30/2026 1100702460
Principal investigator 1 ABBVIE INC. $1,850.00 02/01/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 1100702480
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $49,880.27 01/26/2024 Non-covered Recipient Entity
Valencia Medical and Research Center
C3300-201 No dispute reported 06/30/2026 1150189462
Principal investigator 1 Ardelyx, Inc. $9,995.50 01/08/2024 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1146667559
Principal investigator 1 ABBVIE INC. $7,800.00 01/04/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER
A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) No dispute reported 06/30/2026 1100698041
Principal investigator 1 ABBVIE INC. $2,857.00 01/04/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 1100698043
Principal investigator 1 ABBVIE INC. $3,488.00 01/04/2024 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 1100698045